MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--VIVUS, Inc. (NASDAQ: VVUS), a pharmaceutical company dedicated to the development and commercialization of novel therapeutic products addressing obesity and sexual health, today announced the formation of its Qnexa™ Scientific Advisory Board (the “Qnexa SAB”), consisting of six well known experts in the areas of obesity, trial design, psychology and diabetes. The company has appointed Dr. David Allison, Dr. Nancy Bohannon, Dr. Arthur Frank, Dr. Donna Ryan, Dr. Xavier Pi-Sunyer and Dr. Tom Wadden to the Qnexa SAB. These experts will provide guidance concerning upcoming Qnexa phase 3 clinical trials.
